JVPLabs

What JVPLabs does

JVPLabs (legal entity: JRAS Medical Inc.) is a Canadian medical device company founded in 2016 and headquartered in Newfoundland and Ontario. The company is developing JVPClinic, a single non-invasive medical device built on a patented ECG-gated optical imaging platform that measures subtle changes in neck vein distension to compute Jugular Venous Pressure (JVP) height — a clinical indicator of cardiac filling pressures and right-sided heart function in congestive heart failure (CHF) patients. The technology uses computer vision to convert the traditionally subjective bedside JVP assessment into a standardized, reproducible measurement, applicable in both hospital and home environments across the continuum of heart failure care.

The company is currently pre-revenue: JVPClinic is undergoing regulatory review and is not authorized for sale by Health Canada or the FDA. JVPLabs plans a hardware sales business model with direct enterprise field sales targeting hospitals, health systems, and clinical professionals, with a secondary value proposition for CHF patients and a clear economic case to health system payers (Medicare, insurers) given CHF's status as the single biggest cost driver for Medicare and the leading cause of 30-day hospital readmissions.

The company is supported by a broad coalition of Canadian innovation and funding partners (NRC-CNRC, Atlantic Canada Opportunities Agency, Government of Newfoundland and Labrador, MaRS Discovery District, Communitech, Springboard, Venture Lab, Innovate Newfoundland, M2D2) and has secured public endorsements from Mayo Clinic, GE HealthCare, NL Health Services, and Transform HF. It is led by CEO Andrew Smith, M.D., M.Sc., VP Technology Michele Roberts, and VP Finance Robyn Lundrigan, with independent board members from BDC Capital and the broader health technology community.

Name

JVPLabs

Legal name

JRAS Medical Inc.

Website

https://jvplabs.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

JVPLabs is a Canadian medical device company developing JVPClinic, a patented non-invasive ECG-gated optical imaging device that standardizes Jugular Venous Pressure measurement for congestive heart failure management across hospital and home settings, currently in regulatory review.

Ownership category

akta.pro rank

Product category

Cardiac Diagnostic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

akta.pro secondary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

Keywords

• Non-invasive cardiac monitoring
• Heart failure diagnostics
• Medical imaging devices
• Jugular venous pressure measurement
• Cardiac filling pressure assessment

Headquarters

HQ city

St. John's

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Medical Device Sales (Planned): The company plans to generate revenue through sales of its JVPClinic medical device to healthcare systems, hospitals, and outpatient clinics. The device is currently undergoing regulatory review and is not yet authorized for sale by Health Canada or the FDA.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

JVPLabs develops JVPClinic, a non-invasive medical device that uses a patented ECG-gated optical imaging platform to measure Jugular Venous Pressure (JVP) height, a clinical indicator of cardiac filling pressures in heart failure patients. The device automates the traditionally subjective JVP assessment into a standardized, real-time measurement for proactive CHF care across hospital and home settings. The product is currently undergoing regulatory review by Health Canada and the FDA and is not yet authorized for sale.

Product overview

JVPLabs offers a single unified product: JVPClinic, a non-invasive medical device that uses proprietary ECG-gated optical imaging technology to measure cardiac filling pressures through automated Jugular Venous Pressure (JVP) assessment. The device is designed for heart failure patients across the care continuum, enabling both hospital-based monitoring and home-based patient self-monitoring. The technology transforms the traditionally subjective JVP assessment into a standardized, objective clinical tool. The product is currently undergoing regulatory review and is not yet authorized for sale by Health Canada or the FDA.

Differentiator

Problem solved

Functional benefit

Brands

• JVPClinic: A breakthrough non-invasive medical device designed to measure cardiac filling pressures using ECG-gated optical imaging technology. Currently undergoing regulatory review and not yet authorized for sale by Health Canada or the FDA.

Products and services

• JVPClinic

Quantifiable outcome

• Significantly reduces cost of CHF care across the continuum
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• NACO (National Angel Capital Organization)coreGTM or Marketing Partner · 1 January 2025Recognized by NACO as one of Canada's Top 20 Moonshot Ventures of 2025, providing visibility and credibility as an emerging company with transformative solutions.
• Transform HFcoreStrategic or Co-development PartnerStrategic partner providing clinical validation and endorsement. Transform HF supports the technology as a tool to standardize care within hospital systems and facilitate effective monitoring in home settings.

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Direct peers

• Abbott (CardioMEMS HF System): Abbott's CardioMEMS is an implanted pulmonary artery pressure sensor for remote heart failure monitoring, directly competing with JVPLabs' non-invasive JVP-based approach to reduce CHF readmissions.
• Nonin Medical: Nonin Medical manufactures non-invasive pulse oximetry and patient monitoring devices used across hospital and home settings, making it a directly comparable hardware-focused competitor with overlapping distribution and clinical channels.
• Sensible Medical Innovations (ReDS): ReDS is a non-invasive lung fluid measurement device for heart failure management, competing for the same clinician workflow of objective fluid status assessment that JVPLabs targets via neck vein imaging.

Broad incumbents

• Medtronic: Medtronic has substantial heart failure diagnostic and monitoring franchises (e.g., LINQ ICM, connected cardiac diagnostics) and could leverage scale to compete in CHF ambulatory monitoring as JVPLabs enters the market.
• Philips (Patient Monitoring): Philips provides hospital and remote patient monitoring solutions for cardiovascular care, including telehealth programs targeting CHF readmission reduction, placing it in direct workflow competition with JVPLabs.
• GE HealthCare: GE HealthCare is a broad patient monitoring incumbent that has publicly endorsed JVPLabs' JVP technology and could become either a channel partner or a competitive substitute via its existing bedside monitoring portfolio.
• Edwards Lifesciences: Edwards produces the Swan-Ganz catheter, the gold standard for invasive hemodynamic monitoring in heart failure. While invasive, it competes with JVPLabs for cardiac filling pressure measurement decisions in critical care cardiology.

Emerging players

• CardiacSense: CardiacSense develops wearable continuous cardiac monitoring devices targeting arrhythmia and CHF monitoring, offering a competing form factor for non-invasive, long-duration heart failure assessment.
• HeartFlow: HeartFlow uses non-invasive cardiac imaging and AI for coronary disease assessment; it shares the non-invasive cardiac imaging AI paradigm that JVPLabs uses for JVP measurement, and addresses overlapping cardiology decision-makers.
• Biofourmis: Biofourmis provides AI-driven remote monitoring and analytics for heart failure and other chronic conditions, representing a software-centric competitor to JVPLabs' hardware approach for home CHF management.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/jvplabs
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/jvplabs

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about JVPLabs